- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03462615
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Malaria during pregnancy remains an important public health issue in endemic countries. Most cases of malaria in pregnant women are asymptomatic, and can contribute to adverse outcomes, such as maternal and neonatal anaemia as well as low birth weight. Infections that do not cause symptoms (sub-clinical infections) - particularly in low transmission settings -remain difficult to diagnose during pregnancy but can contribute to adverse outcomes e.g. growth restriction, premature birth, miscarriage and stillbirth.
The Bill & Melinda Gates Foundation (BMGF) has supported the development of an HRP2-based high sensitivity rapid diagnostic tests (HS-RDT) that has analytical sensitivity ten times better than current RDTs and a sensitivity near 80% when compared to the 'gold standard' of quantitative polymerase chain reaction (qPCR). In this regard, the new HS-RDT may be a promising diagnostic and screening test for subclinical malaria during pregnancy.
The overall aim is to compare the performance of novel high sensitivity rapid detection tests with conventional rapid diagnostic tests for Plasmodium falciparum malaria infection in pregnant women in Papua New Guinea
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
All women must meet all the following inclusion criteria in order to be eligible to participate in the study:
- Pregnant women attending first antenatal care visit at selected health facilities
- Resident in the study area for at least 1 year prior to enrolment
- Age ≥ 16
- Willing to freely participate with signed informed consent (or, if illiterate, provide a thumbprint in the presence of an independent witness)
- Willing to provide finger-prick blood sample
Exclusion Criteria:
Women meeting any of the following exclusion criteria at screening will be excluded from study participation:
- History of malaria or antimalarial drugs used in the last three months, as recalled or documented in health record
- Presence of severe malaria as defined by WHO guidelines at the moment of recruitment.
Presence of symptoms and signs of other serious chronic disease such as severe anaemia, tuberculosis and/or central nervous system infections, as defined by WHO guidelines
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic accuracy
Time Frame: 1 year
|
1.1 Estimates of sensitivity, specificity, negative predictive value, positive predictive value, and diagnostic odds ratio of HRP2 HS-RDT for the detection of P. falciparum during pregnancy, compared with conventional good quality RDTs, microscopy and LAMP in peripheral blood with qPCR as reference test.
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7815-2/2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diagnoses Disease
-
Inspirata Europe Ltd.CompletedDiagnoses DiseaseUnited Kingdom
-
Shanghai Chest HospitalUnknownDiagnoses DiseaseChina
-
Nazan Kocak TopbasMersin UniversityNot yet recruiting
-
Brigham and Women's HospitalCricoActive, not recruiting
-
Istanbul Bilgi UniversityUnknown
-
Hospital do CoracaoCompletedInpatient Facililty DiagnosesBrazil
-
Nagaoka Red Cross HospitalUnknownOther Diagnoses and ConditionsJapan
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
Doha FahmyAssiut UniversityUnknownDiagnoses Disease
Clinical Trials on HS-RDT
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversidad de AntioquiaCompletedDiagnoses Disease | Plasmodium Falciparum | Pregnancy MalariaColombia
-
Universidad Nacional de ColombiaCompleted
-
University of California, San FranciscoHealth Poverty Action; Center for Malariology, Parasitology, and Entomology; The...CompletedPlasmodium Falciparum MalariaLao People's Democratic Republic
-
University Research Co, LLCDuke University; United States Agency for International Development (USAID); Centers... and other collaboratorsUnknownMalaria,Falciparum | Malaria DiagnosisMyanmar
-
London School of Hygiene and Tropical MedicineHealthNet TPO; Health Protection and Research Organisation; Medical Emergency...CompletedPneumonia | Fever | Malaria | Acute Febrile IllnessAfghanistan
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.CompletedTreatment Resistant Depressive DisorderChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting